Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
NCT06721013 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of the phase 1 part of this study is to evaluate how well pirtobrutinib is tolerated and what side effects may occur. The phase 2 part of the study will further investigate efficacy and safety of multiple pirtobrutinib dosages versus placebo. The study drug will be administered orally in participants with Primary Immune Thrombocytopenia (ITP). Blood tests will be performed to check how much pirtobrutinib gets into the bloodstream and how long it takes the body to eliminate it. The study will last up to approximately 16 weeks for phase 1 dose-escalation and 28 weeks for phase 2 dose-optimization, excluding screening.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pirtobrutinib
Study Locations (20)
Other
- Nanfang Hospital of Southern Medical University — Guangzhou
- Qilu Hospital of Shandong University — Jinan
- Hematology Hospital of the Chinese Academy of Medical Sciences — Tianjin
- Union Hospital Tongji Medical College Huazhong University of Science and Technology — Wuhan
- OUH — Odense C
- Hôpital Henri Mondor — Créteil
- CHU Dijon - Hopital du Bocage — Dijon
- CHU Bordeaux - Hôpital Haut-Lévêque — Pessac
- Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS — Bologna
Texas
- Texas Oncology - Central South — Austin
- MD Anderson Cancer Center — Houston
- Texas Oncology Gulf Coast — The Woodlands
California
- USC Norris Comprehensive Cancer Center — Los Angeles
- Stanford University — Stanford
District of Columbia
- MedStar Georgetown University Hospital — Washington D.C.
Florida
- University of Miami Hospital and Clinics Sylvester Comprehensive Cancer Center — Miami
Illinois
- Bleeding and Clotting Disorders Institute — Peoria
Louisiana
- Ochsner Clinical Foundation — New Orleans
Minnesota
- Mayo Clinic — Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2025-07-30 |
| Est. Completion | 2027-02 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06721013
The ClinicalTrials.gov registry entry for NCT06721013 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 704 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Immune Thrombocytopenia (ITP) appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06721013 reports 20 study locations spanning 9 distinct geographic areas — top geographies include Other, Texas, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06721013 about?
NCT06721013 is a clinical study titled "A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia". The purpose of the phase 1 part of this study is to evaluate how well pirtobrutinib is tolerated and what side effects may occur. The phase 2 part of the study will further investigate efficacy and safety of multiple pirtobrutinib dosages versus placebo. The study drug will be administered orally i...
What is the current status of trial NCT06721013?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2025-07-30. Estimated completion is 2027-02.
What conditions does trial NCT06721013 study?
This clinical trial studies the following conditions: Immune Thrombocytopenia (ITP). These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06721013?
The interventions under investigation include: Placebo (DRUG), Pirtobrutinib (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06721013?
This trial is sponsored by Eli Lilly and Company, which has 704 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06721013 being conducted?
This trial has 20 study locations across California, District of Columbia, Florida, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.